Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.34 |
| ▸ | GBA1 | P04062 | 3/20 | 0.33 |
| ▸ | CES1 | P23141 | 5/20 | 0.32 |
| ▸ | FAAH | O00519 | 4/20 | 0.32 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1519541 | 0.86 | GBA1 (0.33) | GBA1CA1CA2MMP1MMP2 | |
| SCHEMBL12765425 | 0.85 | TSHR (0.36) | GBA1 | |
| SCHEMBL27109977 | 0.76 | CASP2 (0.44) | PPARGCES1FAAHCES2CA1 | |
| SCHEMBL16181428 | 0.76 | HSP90AA1 (0.42) | CES1FAAHCES2CA1CA2 | |
| SCHEMBL13300477 | 0.74 | CA1 (0.36) | PPARGCA1CA2 | |
| SCHEMBL8292803 | 0.73 | HSP90AA1 (0.53) | PPARGCES1FAAHCES2 | |
| SCHEMBL8292801 | 0.73 | HSP90AA1 (0.53) | PPARGCES1FAAHCES2 | |
| SCHEMBL4397589 | 0.72 | FAAH (0.44) | CES1FAAHCES2 | |
| SCHEMBL4732709 | 0.70 | HSP90AA1 (0.53) | PPARGCES1FAAHCES2 | |
| SCHEMBL14166663 | 0.70 | HSP90AA1 (0.48) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160108102-A1 | Novel GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2016-04-21 | — | — | US | disclosed |
| US-20160108102-A1 | Novel GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2016-04-21 | — | — | US | disclosed |
| US-20130244931-A1 | Novel GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2013-09-19 | — | — | US | disclosed |
| US-20130244931-A1 | Novel GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2013-09-19 | — | — | US | disclosed |
| US-20130053315-A1 | NOVEL GLP-1 DERIVATIVES | NOVO NORDISK A/S | 2013-02-28 | — | — | US | disclosed |
| US-20130053315-A1 | NOVEL GLP-1 DERIVATIVES | NOVO NORDISK A/S | 2013-02-28 | — | — | US | disclosed |
| US-20130040884-A1 | ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG | NOVO NORDISK A/S | 2013-02-14 | — | — | US | disclosed |
| US-20130040884-A1 | ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG | NOVO NORDISK A/S | 2013-02-14 | — | — | US | disclosed |
| US-20100305032-A1 | Novel GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2010-12-02 | — | — | US | disclosed |
| US-20100305032-A1 | Novel GLP-1 Derivatives | NOVO NORDISK A/S (DK) | 2010-12-02 | — | — | US | disclosed |
| US-20070203058-A1 | Novel Glp-1 Derivatives | NOVO NORDISK A/S (DK) | 2007-08-30 | — | — | US | disclosed |
| US-20070203058-A1 | Novel Glp-1 Derivatives | NOVO NORDISK A/S (DK) | 2007-08-30 | — | — | US | disclosed |
| WO-2005027978-A2 | ALBUMIN-BINDING DERIVATIVES OF THERAPEUTIC PEPTIDES | NOVO NORDISK A/S (DK) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040884-A1 | ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG | FABP1, FABP2, FABP4 | PPARG 65/4885GBA1 1479/4885CES1 132/4885 |
| US-20130053315-A1 | NOVEL GLP-1 DERIVATIVES | GLP1R, GIPR, IAPP | PPARG 279/4885GBA1 3971/4885CES1 1628/4885 |
| US-20160108102-A1 | Novel GLP-1 Derivatives | GLP1R, GIPR, IAPP | PPARG 279/4885GBA1 3971/4885CES1 1628/4885 |
| US-20100305032-A1 | Novel GLP-1 Derivatives | GLP1R, GIPR, IAPP | PPARG 279/4885GBA1 3971/4885CES1 1628/4885 |
| US-20070203058-A1 | Novel Glp-1 Derivatives | GLP1R, GIPR, NPY4R | PPARG 1119/4885GBA1 4478/4885CES1 1666/4885 |
| US-20130244931-A1 | Novel GLP-1 Derivatives | GLP1R, GIPR, IAPP | PPARG 279/4885GBA1 3971/4885CES1 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.